Publicacions en col·laboració amb investigadors/es de University of Pavia (28)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Clinical practice in European centres treating paediatric posterior fossa tumours with pencil beam scanning proton therapy

    Radiotherapy and Oncology, Vol. 198

  3. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  4. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

    Journal of neurology, neurosurgery, and psychiatry, Vol. 95, Núm. 10, pp. 927-937

  5. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

  6. The cellular prion protein does not affect tau seeding and spreading of sarkosyl-insoluble fractions from Alzheimer’s disease

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  3. Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes

    The Lancet. Oncology, Vol. 24, Núm. 1, pp. 91-106

2022

  1. An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis

    Leukemia, Vol. 36, Núm. 8, pp. 2076-2085

  2. Deconvolution of the hematopoietic stem cell microenvironment reveals a high degree of specialization and conservation

    iScience, Vol. 25, Núm. 5

  3. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

    European Journal of Haematology, Vol. 108, Núm. 1, pp. 73-83

  4. Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery

    BJS Open, Vol. 6, Núm. 1

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis

    Blood Cancer Journal, Vol. 11, Núm. 2

  3. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

    Blood Cancer Journal, Vol. 11, Núm. 12

  4. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

    Blood, Vol. 138, Núm. 17, pp. 1583-1589

2020

  1. Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: An analysis from the European Society for Blood and Marrow Transplantation

    ESMO Open, Vol. 5, Núm. 5

2018

  1. Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel

    Journal of Hematology and Oncology, Vol. 11, Núm. 1

2015

  1. VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab

    Journal of Neuro-Oncology, Vol. 121, Núm. 3, pp. 499-504